New depression drug NH102 begins human safety testing

NCT ID NCT07324408

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested the safety and tolerability of a new drug called NH102 in 40 healthy adults. Participants received either the drug or a placebo to check for side effects and how the drug moves through the body. The study is complete, but it does not yet test if NH102 works for depression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

NH102 (oral tablet)

What this could lead to

If successful, this could lead to a new treatment option for depression.

What could go wrong

This is a very early Phase 1 trial in healthy volunteers, not people with depression. It only tests safety and dosing, not whether the drug works for depression. Many drugs fail at this stage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai Mental Health Center

    Shanghai, Shanghai Municipality, 201108, China